Xarelto

Xarelto Judge Taps Attorneys to Allocate $93M in Fees to Leading Firms

The federal judge handling the $775 million settlement over the blood thinner Xarelto has established a committee of five attorneys to assess how up to $93 million set aside for leading plaintiffs firms should be doled out.

U.S. District Judge Eldon Fallon of the Eastern District of Louisiana tapped Pensacola, Florida, attorney Brian Barr of Levin Papantonio Thomas Mitchell Rafferty & Proctor; Andy Birchfield of Beasley Allen in Montgomery, Alabama; Leonard Davis of Herman Herman & Katz in New Orleans; Gerald Meunier of Gainsburgh, Benjamin, David, Meunier & Warshauer, also in New Orleans; and Levin Sedran & Berman attorney Michael Weinkowitz in Philadelphia to form what the judge referred to as a “fee allocation liaison counsel” in the Xarelto litigation. The attorneys will be tasked with coming up with a recommendation for how the court should divide up the common benefit fund.

How Much Will It Cost Johnson & Johnson To Settle Most of Its Lawsuits?

Johnson & Johnson has been facing several lawsuits over its different products, including talc, hip-plants, and the blood thinner, Xarelto. There are a total of around 50,000 such cases against the company. The company has agreed to settle several of these cases, as announced over the last few months. However, if it were to settle all of the above 50,000 cases, it would cost the company an amount north of $6 billion, in our view. Johnson & Johnson is capable of settling all the claims if need be from its cash in hand of $14 billion. View our interactive dashboard analysis ~ How Much Money Could Johnson & Johnson Have To Shell Out To Settle Its Lawsuits? 

Bayer, J&J settle U.S. Xarelto litigation for $775 million

Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed.

The amount will be shared equally between the two companies that jointly developed the drug. Bayer and J&J do not admit liability under the agreement.

The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs.

Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information.

Johnson & Johnson and Bayer to pay $775M to settle Xarelto suits

Johnson & Johnson and Bayer agreed Monday to pay $775 million to settle almost 25,000 lawsuits in connection to blood thinner Xarelto.

Each company will pay 50 percent of the settlement, according to The New York Times. The payment ends both state and federal cases — the New Brunswick, New Jersey-based Johnson & Johnson jointly markets Xarelto with Bayer, which is based in Germany.

Patients sued both companies, which failed to issue warnings regarding possible fatal bleeding episodes connected to taking Xarelto. Neither company accepted liability and actually won all six lawsuits that went to trial.

“Even in the face of meritless allegations, and even while winning in court, complex litigation demands an enormous amount of time and resources,” the pharmaceutical division of Johnson & Johnson explained in a statement regarding the settlement.

Bayer, J&J settle blood thinner Xarelto litigation for $775 million

KEY POINTS
Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed.
The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs.
Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information.

Bayer and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed.

The amount will be shared equally between the two companies that jointly developed the drug. Bayer and J&J do not admit liability under the agreement.

The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs.

Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information.

Bayer in a statement on Monday said it continues to believe the claims are without merit.

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in a plaintiffs’ legal claim. Words such as ‘loans,’ ‘lender,’ 'interest', ‘borrower,’ and phrases such as 'lawsuit loans' and 'settlement loans' are used for relatability, search, and marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408